[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"covid\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:covid":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,41,121,150,176,203,234,269,293,320,341,364,384],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100388919","assessment-of-chilbains-occuring-during-covid-19-infection-100388919",false,"NCT04344119","Assessment of Chilbains Occuring During Covid-19 Infection","Assessment of Skin Manifestations Occuring During Covid-19 Infection With a Special Focus on Chilbains","ChilblainCOVID","Inclusion Criteria:\n\n* All patients with proven covid infection (using PCR, serum antibody or lung TDM) and presenting at least one cutaneous lesions that occurred during the infection.","ALL","90 Years",{"count":20,"type":21},30,"ESTIMATED","OBSERVATIONAL","Some patients infected by covid-19 develop skin manifestations. These manifestations are still not well known and there pathophysiology remain unclear. Among them, acral manifestation resembling to chilblains appears frequent and quite specific. The aim of this project is to better characterize the cutaneous manifestations occurring during Covid-19 infection with a special focus on chilblains. These acral manifestation could be due to a direct viral effect, but also to microthrombosis or vascularitis. Understanding the pathomechanisms involved could provide interesting clue for understanding not only the skin manifestations but also some of the other systemic symptoms associated to covid-19 infection. This study plan to characterize these acral manifestations by analyzing the clinical and dermoscopic patterns and to correlate them with the non-invasive vascular explorations but also immune and coagulopathy explorations that are done in the CHU of Nice in covid-19 patients.",[25,26,27],"Skin Manifestations","COVID","Chilblains","RECRUITING","2026-06-25",{"date":31,"type":32},"2026-06-29","ACTUAL",{"date":34,"type":32},"2020-04-09",{"date":36,"type":21},"2027-06-25",{"name":38,"class":39},"Centre Hospitalier Universitaire de Nice","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":47,"targetDuration":49,"studyType":22,"phases":4,"briefSummary":50,"conditions":51,"keywords":94,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":120},"100320510","synergy-ai-artificial-intelligence-based-precision-oncology-clinical-trial-matching-and-registry-100320510","NCT03452774","SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry","Inclusion Criteria:\n\n* Pts with solid and hematological malignancies;\n* Pts cancer-related biomarkers, gene variants, fusion and rearrangements (by immunohistochemistry, PCR, FISH or NGS): PD-L1, MSI (MMR), Claudin18.2, HER2\u002FNeu, Tumor mutational burden\u002Fload (TMB), ABL1, ACVR1B, AKT1, AKT2, AKT3, ALK, APC, AR, ATM, ATRX, AURKA, AURKB, BAP1, BCL2, BCL6, BRAF, BRCA1, BRCA2, BTK, CCND1, CCND2, CCND3, CDK4, CDK6, CDKN1A\u002FB, CEBPA, CHEK1, CHEK2, CSF1R, CTNNB1, DAXX, DDR1\u002F2, DNMT3A, EGFR, ERBB2, ERBB3, ERBB4, ERCC4, ER, ESR1, FANCA, FAS, FBXW7, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GATA3, GATA6, GNAS, HDAC1, HGF, HRAS, IDH1, IDH2, IGF1R, JAK1, JAK2, JAK3, KDR (VEGFR2), KIT, KRAS, MAP2K2 (MEK2), MAP3K1, MCL1, MDM2, MDM4, MEN1, MET, MSH2, MSH3, MSH6, MTOR, MUTYH, MYC, MYCL (MYCL1), NF1, NF2, NOTCH1, NPM1, NRAS, NTRK1, NTRK2, NTRK3, PALB2, PARP1, PARP2, PARP3, PBRM1, PDCD1 (PD1), PDCD1LG2 (PD-L2), PDGFRA, PDGFRB, PIK3C, PMS2, POLD1, POLE, PRDM1, PTCH1, PTEN, RAF1, RB1, RET, RICTOR, ROS1, RPTOR, SDHA\u002FB\u002FC, SMAD, SMARC, SMO, STK11, TGFBR2, TP53, TSC1, TSC2, VEGFA, VHL, WT1, ZNF217, ZNF703, CEACAM, NRG1, among others.\n\nThese biomarkers should be determined by local laboratory, external vendor, or next generation sequencing platform\n\n* Decision to consider clinical trial pre-screening enrollment (CTE) by primary provider and\u002For patient\n\nExclusion Criteria:\n\n* ECOG PS \\> 2;\n* Abnormal organ function;\n* Hospice enrollment",{"count":48,"type":21},50000,"36 Months","International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.",[52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,26,87,88,89,90,91,92,93],"Cancer, Metastatic","Cancer","Cancer of Pancreas","Cancer of Liver","Cancer of Stomach","Cancer Liver","Cancer of Rectum","Cancer of Kidney","Cancer of Esophagus","Cancer of Cervix","Cancer of Colon","Cancer of Larynx","Cancer, Lung","Cancer, Breast","Cancer, Advanced","Cancer Prostate","Cancer of Neck","Cancer of Skin","Neuroendocrine Tumors","Carcinoma","Mismatch Repair Deficiency","BRCA Gene Rearrangement","Non Hodgkin Lymphoma","Leukemia","Non Small Cell Lung Cancer","Cholangiocarcinoma","Glioblastoma","Central Nervous System Tumor","Melanoma","Urothelial Carcinoma","Bladder Cancer","Ovarian Cancer","Endometrial Cancer","Testicular Cancer","Breast Cancer","Myelofibrosis","Myeloproliferative Neoplasm","Myeloproliferative Disorders","Follicular Lymphoma","Mantle Cell Lymphoma","Marginal Zone Lymphoma","Myelodysplastic Syndromes",[95,96,97,98,99,100,101,102,103,104,105,106,107,108,109],"artificial intelligence","virtual tumor board","clinical trial","clinical trial matching","electronic medical record","machine learning","cost of care","targeted therapy","immunotherapy","precision medicine","precision oncology","cancer","value based care","real world data","data analytics","2025-10-25",{"date":112,"type":32},"2025-10-28",{"date":114,"type":32},"2018-01-01",{"date":116,"type":21},"2040-06",{"name":118,"class":119},"Massive Bio, Inc.","INDUSTRY",68,{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":130,"conditions":131,"keywords":134,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":149},"100609939","prospective-clinical-evaluation-of-the-biofire-emerging-coronavirus-panel-for-the-detection-of-covid-19-and-other-coronaviruses-100609939","NCT07221097","Prospective Clinical Evaluation of the BioFire Emerging Coronavirus Panel for the Detection of COVID-19 and Other Coronaviruses","Prospective Clinical Evaluation of the BioFire Emerging Coronavirus Panel - Sponsor's Protocol","Inclusion Criteria:\n\n* Specimen is residual NPS in transport medium (VTM or UTM) left over from standard of care testing under clinician order for respiratory pathogen analysis.\n* Specimen has been held at room temperature for less than or equal to 4 hours or 4°C for less than or equal to 72 hours before enrollment.\n* At least 1.7 mL of specimen is remaining after standard of care testing and available for use in the study\n\nExclusion Criteria:\n\n* Specimen is unable to be tested within the defined storage parameters\n* Insufficient specimen volume for testing\n* Transport medium type is unknown",{"count":129,"type":21},1500,"The Biomedical Advanced Research and Development Authority (BARDA) has contracted BioFire Defense (BFDf) to develop the BioFire Emerging Coronavirus (ECoV) Panel, a nucleic acid test capable of detecting coronaviruses from nasopharyngeal swab (NPS) in transport medium.\n\nThis study aims to evaluate the diagnostic accuracy of the assays comprising the BioFire ECoV Panel. It is hypothesized that the BioFire ECoV Panel assays will be highly sensitive and specific for the detection of the coronaviruses included on the panel.",[132,133,26],"Coronavirus","Respiratory Infection",[135,136,137,138,139],"in vitro diagnostic","pandemic preparedness","medical device","molecular diagnostic","coronavirus","2025-10-23",{"date":142,"type":32},"2025-10-27",{"date":144,"type":32},"2025-09-29",{"date":146,"type":21},"2026-08",{"name":148,"class":119},"BioFire Defense LLC",6,{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":157,"sex":17,"minAge":158,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":161,"phases":162,"briefSummary":164,"conditions":165,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":175},"100573313","clinical-validation-of-the-aptitude-medical-systems-metrix-covid-19-test-100573313","NCT06744660","Clinical Validation of the Aptitude Medical Systems Metrix COVID-19 Test","Clinical Validation of the Aptitude Medical Systems Metrix COVID-19 Test for Detection of SARS-CoV-2 in Point-of-Care and At-Home (OTC)\u002FNon-Laboratory Settings","Inclusion Criteria:\n\n1. Participant or guardian understands and is able and willing to provide written informed consent, and assent where applicable, prior to study enrollment.\n2. Male or female aged 2 years or older\n3. Participant is currently exhibiting fever, or one or more symptoms of respiratory tract infection (such as, but not limited to, chills, cough, shortness of breath or difficulty breathing, fatigue, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting or diarrhea). Participant must still be exhibiting symptoms on the day of sample collection.\n4. Participant or guardian agrees to read, and is able to read with understanding, the AN swab QRI prior to beginning the operation of each of the Metrix COVID-19 Test.\n5. Participant or guardian is able and willing to contribute the required swab samples for testing and understands and is able and willing to sign the study informed consent.\n\nExclusion Criteria:\n\n1. Participant does not understand and\u002For is not able and willing to sign the study informed consent and\u002For assent.\n2. Participant or guardian is not able to comply with nasal swab collection requirements following the QRI.\n3. Participant has previously provided a sample for the study.\n4. Participant is not able to tolerate sample collection.\n5. Participant is currently undergoing antiviral treatment such as baloxavir marboxil (trade name Xofluza®), oseltamivir (Tamiflu®), zanamivir (Relenza®), and peramivir (Rapivab®).\n6. Participants currently undergoing treatment and\u002For within the past thirty (30) days with prescription medication to treat novel Coronavirus SARS-CoV-2 infection, which may include but is not limited to Remdesivir (Veklury), Paxlovid, molnupiravir or receiving convalescent plasma therapy for SARS-CoV-2.\n7. Participants who have had a nasal wash or aspirate as part of their standard of care treatment on day of study visit prior to the study sample collection.\n8. Participants who have had recent craniofacial injury or surgery, including to correct deviation of the nasal septum, within the previous six (6) months.\n9. Participants who do not understand\u002Fread the English language.",true,"2 Years",{"count":160,"type":21},1000,"INTERVENTIONAL",[163],"NA","The Metrix COVID Test will be evaluated for use in Point-of-Care and Non-Laboratory settings in a home testing environment utilizing the clinical study design described herein. The study will take place in simulated home environments which will be set up within or near active clinical settings (e.g., urgent care facilities). This will be a prospective study conducted at three or more investigational sites located within the United States for the clinical validation of the Metrix COVID Test for the detection of SARS-CoV-2 AN swab samples. Additional sites may be added to the study in order to meet minimum subject\u002Fsample enrollment requirements and geographic prevalence of respiratory virus infections. Comparator testing will be performed to determine the infection status of each sample for comparison to results generated by the candidate test. The primary comparator for the study will be an FDA-cleared assay for the detection of SARS-CoV-2.",[166,26],"COVID-19",{"date":168,"type":32},"2025-10-02",{"date":170,"type":32},"2024-10-17",{"date":172,"type":21},"2025-12-01",{"name":174,"class":119},"Aptitude Medical Systems",3,{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":17,"minAge":184,"maxAge":185,"enrollmentInfo":186,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":188,"conditions":189,"keywords":190,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":40},"100390302","long-term-impact-of-infection-with-novel-coronavirus-covid-19-100390302","NCT04362150","Long-term Impact of Infection With Novel Coronavirus (COVID-19)","Long-term Impact of Infection With Novel Coronavirus (LIINC): An Observational Study","LIINC","Inclusion Criteria:\n\n1. Willing and able to provide written informed consent, and\n2. Age \\>\u002F= 18 years, and\n3. A history of SARS-CoV-2 infection, as evidenced by:\n\n   1. Available laboratory documentation of SARS-CoV-2 RNA positivity on a nucleic acid amplification test or by serologic testing when this becomes available, or\n   2. Reference by the participant to a laboratory test performed on respiratory tract secretions or blood, fingerstick, or saliva test that was reported to the participant to be positive for SARS-CoV-2 or COVID-19 infection,\n4. And a period of 21 days or more has elapsed since the first positive test or symptoms preceding the first positive test, whichever is earlier.\n\nExclusion Criteria:\n\n1. Self-reported or documented chronic anemia with hemoglobin \\\u003C 9 g\u002FdL. Anemia during a preceding acute illness will not be exclusionary.\n2. Serious medical or psychiatric illness that, in the opinion of the site investigator, would interfere with the ability to adhere to study requirements or to give informed consent.\n3. Active drug or alcohol use or dependence that, in the opinion of the Principal Investigator, would interfere with adherence to study requirements or to give informed consent.","18 Years","100 Years",{"count":187,"type":21},800,"LIINC is a study of volunteers who were previously infected with SARS-CoV-2 (also known as novel coronavirus or COVID-19) who have recovered from acute infection. The study is designed to provide a specimen bank of samples with carefully characterized clinical data. LIINC specimens will be used to examine multiple questions involving the virologic, immunologic, and host factors involved in COVID-19, with a focus on understanding variability in the long-term immune response between individuals.",[26],[166,139,191,192,193],"SARS-CoV-2","Long COVID","post-acute sequelae of SARS-CoV-2","2025-06-09",{"date":196,"type":32},"2025-06-12",{"date":198,"type":32},"2020-04-21",{"date":200,"type":21},"2030-12-31",{"name":202,"class":39},"University of California, San Francisco",{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":157,"sex":17,"minAge":184,"maxAge":4,"enrollmentInfo":210,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":212,"conditions":213,"keywords":221,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":40},"100390125","a-study-to-explore-the-role-of-gut-flora-in-covid-19-infection-100390125","NCT04359836","A Study to Explore the Role of Gut Flora in COVID-19 Infection","A Non-Interventional Pilot Study to Explore the Role of Gut Flora in COVID-19 Infection","Inclusion Criteria:\n\n1. Signed informed consent, demonstrating that the patient understands the procedures required for the study and the purpose of the study\n2. Male or female of 18 years of age or older\n3. Diagnosis of COVID-19 infection by RT- PCR within 1 week of Screening\n\nExclusion Criteria:\n\n1. Refusal to sign informed consent form\n2. History of bariatric surgery, total colectomy with ileorectal anastomosis or proctocolectomy.\n3. Postoperative stoma, ostomy, or ileoanal pouch\n4. Treatment with total parenteral nutrition",{"count":211,"type":21},250,"This study seeks to determine whether the virus which causes COVID-19, SARS-CoV-2, is shed in the stools of patients who are infected.",[214,215,26,166,216,132,217,218,219,220],"Gut Microbiome","Gastrointestinal Microbiome","Corona Virus Infection","Coronaviridae Infections","Coronavirus 19","Coronavirus-19","COVID 19",[222,132,223,224,26,166],"Microbiome","Corona Virus","19","2025-06-02",{"date":227,"type":32},"2025-06-05",{"date":229,"type":32},"2020-04-16",{"date":231,"type":21},"2027-07-31",{"name":233,"class":39},"ProgenaBiome",{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":4,"eligibilityCriteria":240,"healthyVolunteers":11,"sex":17,"minAge":184,"maxAge":4,"enrollmentInfo":241,"targetDuration":4,"studyType":161,"phases":243,"briefSummary":244,"conditions":245,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":40},"100569296","the-effects-of-endotracheal-suctioning-on-pain-and-serum-markers-100569296","NCT06692400","The Effects of Endotracheal Suctioning on Pain and Serum Markers","The Impact of Endotracheal Suctioning on Pain, Hypoxia, and Oxidative Stress Biomarkers in Intubated Adult ICU Patients: A Controlled Trial","Inclusion Criteria:\n\n* Adults (aged 18 years and older)\n* Current diagnosis of flu, pneumonia, COVID, or sepsis\n* Intubated and receiving mechanical ventilation.\n* Have arterial lines placed\n* Require endotracheal suctioning as part of their care\n\nExclusion Criteria:\n\n* Patients receiving neuromuscular blocking agents\n* Contraindications for blood draws (hemoglobin levels below 8.0 g\u002FdL; Jehovah's Witness)",{"count":242,"type":21},110,[163],"The goal of this experimental study is to understand if endotracheal tube (ETT) suctioning increases pain and causes stress on the body in intubated adult ICU patients. These patients are already on ventilators, which means they need suctioning to keep their airways clear, but this procedure may be uncomfortable and cause stress.\n\nThe main questions this study aims to answer are:\n\nDoes ETT suctioning raise pain levels as measured by the Critical-Care Pain Observation Tool (CPOT)? Does ETT suctioning increase certain chemicals in the blood (hypoxanthine, xanthine, and uric acid) that show stress and lack of oxygen in the body? Researchers will compare patients who have ETT suctioning (intervention group) with those who do not have suctioning during the study period (control group) to see if there are differences in pain and blood markers of stress.\n\nParticipants will:\n\nHave pain measured before and after suctioning using the CPOT. Have blood samples taken from an existing line at three time points: 5 minutes before, 5 minutes after, and 30 minutes after suctioning.\n\nProvide demographic information (like age, gender, and diagnosis) from medical records.\n\nThis research will help improve how pain is managed for ICU patients who cannot speak for themselves, potentially leading to better pain relief methods in the future.",[246,247,248,249,250,251,252,253,254,255,256,257,26,258,259],"Intensive Care Unit ICU","Intubation","Critical Illness","Mechanical Ventilation","Pain Measurement","Pain, Procedural","Oxidative Stress","Hypoxia","Biomarkers \u002F Blood","Adult","Uric Acid","Sepsis","Influenza","Pneumonia","2025-05-19",{"date":262,"type":32},"2025-05-21",{"date":264,"type":32},"2025-01-30",{"date":266,"type":21},"2026-04",{"name":268,"class":39},"Loma Linda University",{"id":270,"slug":271,"hasResults":11,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":275,"eligibilityCriteria":276,"healthyVolunteers":11,"sex":17,"minAge":277,"maxAge":4,"enrollmentInfo":278,"targetDuration":280,"studyType":22,"phases":4,"briefSummary":281,"conditions":282,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":40},"100397789","covid-19-in-pid-survey-100397789","NCT04459689","COVID-19 in PID Survey","Worldwide COVID-19 in Children and Adult Patients With Primary ImmunoDeficiencies (PID) Survey","COPID19","Inclusion Criteria:\n\n* Diagnosed with a Primary Immune Deficiency\n* COVID-19 (proven or probable)\n\nExclusion Criteria:\n\n* Secondary Immune Deficiency\n* Other Coronovirus infection","0 Years",{"count":279,"type":21},200,"1 Year","With the emergence of SARS-CoV-2 and the COVID-19 pandemic, there is an urgent need to understand the impact of infection on immunodeficient individuals. Whilst co-morbidities (such as diabetes, cancer, arterial hypertension, heart disease...) have been documented in people infected with SARS-CoV-2, there is currently no information on the consequences and outcomes for individuals with primary immunodeficiencies (PID).\n\nFollowing the 1st phase of the survey (launched by Isabelle Meyts (ESID), Nizar Mahlaoui (CEREDIH \\& IPOPI) and Kate Sullivan with Stuart Tangye (IUIS), that gave an idea of the number of affected PID patients and the impact of SARS-CoV-2 and directly focusing on obtaining this top level of information), we are launching the 2nd phase: \"COPID19\".\n\nCOPID19 survey is a secured online GDPR compliant platform based in Paris (Imagine Institute). It has been approved by the Paris-Necker-Enfants malades IRB and Ethics Committee. However, this retrospective survey is designed for global distribution. Data can be entered by a health care professional (mostly clinicians) through a personal login and password.\n\nEach documenting person will have access to his\u002Fher own patients' data. COPID19 require a greater level of information than the 1st phase. The eCRF will be open to evolutions depending on progresses in our knowledge of this pandemic.",[283,26],"Primary Immune Deficiency","2025-03-03",{"date":286,"type":32},"2025-03-05",{"date":288,"type":32},"2020-03-15",{"date":290,"type":21},"2027-02-18",{"name":292,"class":39},"Imagine Institute",{"id":294,"slug":295,"hasResults":11,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":299,"eligibilityCriteria":300,"healthyVolunteers":11,"sex":17,"minAge":184,"maxAge":4,"enrollmentInfo":301,"targetDuration":303,"studyType":22,"phases":4,"briefSummary":304,"conditions":305,"keywords":308,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":40},"100388980","impact-of-covid19-outbreak-in-cardiac-acute-care-100388980","NCT04344912","Impact of COVID19 Outbreak in Cardiac Acute Care","Impact of COVID19 Outbreak in Cardiac Patients Admitted in Intensive Care Unit : the CCU-COVID19 Study","CCU-COVID19","Inclusion Criteria:\n\n* 18 years and older\n* Admitted in the Cardiac Intensive Care Unit from March 20th 2020\n* Patient informed and having expressed his non-opposition to participate in the research\n\nExclusion Criteria:\n\n* Minor patient\n* Patient who expressed opposition to participation in the study",{"count":302,"type":21},500,"12 Months","This registry will evaluate the impact of the COVID19 outbreak on Cardiac patients admitted in the Intensive Care Unit of the Pitie-Salpetriere Hospital in Paris, France",[306,307,26],"Acute Coronary Syndrome","Heart Failure",[309,306,310],"COVID19","Myocardial Infarction","2024-10-11",{"date":313,"type":32},"2024-10-15",{"date":315,"type":32},"2020-03-20",{"date":317,"type":21},"2024-12",{"name":319,"class":39},"Assistance Publique - Hôpitaux de Paris",{"id":321,"slug":322,"hasResults":11,"nctId":323,"briefTitle":324,"officialTitle":324,"acronym":4,"eligibilityCriteria":325,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":184,"enrollmentInfo":326,"targetDuration":328,"studyType":22,"phases":4,"briefSummary":329,"conditions":330,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":339,"locationsCount":40},"100388284","covid-19-in-hospitalised-norwegian-children---risk-factors-outcomes-and-immunology-100388284","NCT04335773","COVID-19 in Hospitalised Norwegian Children - Risk Factors, Outcomes and Immunology","Inclusion Criteria:\n\nSuspected covid-19 infection and age 0-18 years\n\nExclusion Criteria:\n\nAge \\>18 years",{"count":327,"type":21},350,"6 Months","Prospective cohort study of COVID-19 infection among children in Norway.",[331,26,332],"Pediatric Respiratory Diseases","Fatigue Post Viral","2022-02-14",{"date":335,"type":32},"2022-02-16",{"date":337,"type":32},"2020-04-03",{"date":200,"type":21},{"name":340,"class":39},"University Hospital, Akershus",{"id":342,"slug":343,"hasResults":11,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":4,"eligibilityCriteria":347,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":348,"targetDuration":4,"studyType":161,"phases":350,"briefSummary":353,"conditions":354,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":356,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":362,"locationsCount":40},"100389474","phase-2-the-efficacy-of-ivermectin-in-larger-doses-in-covid-19-treatment-100389474","NCT04351347","The Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment","Clinical Study Evaluating the Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment","Inclusion Criteria:\n\n* Patients with covid 19\n\nExclusion Criteria:\n\n* Allergy or side effects to treatment",{"count":349,"type":21},300,[351,352],"PHASE2","PHASE3","Efficacy of Ivermectin in larger doses in COVID-19 treatment",[26],"2021-03-08",{"date":357,"type":32},"2021-03-10",{"date":359,"type":32},"2020-06-16",{"date":361,"type":21},"2030-12-01",{"name":363,"class":39},"Tanta University",{"id":365,"slug":366,"hasResults":11,"nctId":367,"briefTitle":368,"officialTitle":369,"acronym":4,"eligibilityCriteria":370,"healthyVolunteers":11,"sex":17,"minAge":184,"maxAge":4,"enrollmentInfo":371,"targetDuration":4,"studyType":161,"phases":373,"briefSummary":374,"conditions":375,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":382,"locationsCount":383},"100391888","phase-3-novel-regimens-in-covid-19-treatment-100391888","NCT04382846","Novel Regimens in COVID-19 Treatment","Nitazoxanide in Treatment of COVID-19","Inclusion Criteria:\n\n* Patients with COVID-19 infection\n\nExclusion Criteria:\n\n* Allergy or contraindication to the drugs.",{"count":372,"type":21},160,[352],"Nitazoxanide has been shown to have a clinical efficacy against severe acute respiratory syndrome coronavirus 2; ivermectin has also demonstrated a remarkable experimental efficacy with a potential to be used for Coronavirus disease 2019.",[26,216],"2020-12-02",{"date":378,"type":32},"2020-12-04",{"date":380,"type":32},"2020-05-08",{"date":361,"type":21},{"name":363,"class":39},2,{"id":385,"slug":386,"hasResults":11,"nctId":387,"briefTitle":388,"officialTitle":389,"acronym":4,"eligibilityCriteria":390,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":391,"targetDuration":4,"studyType":161,"phases":393,"briefSummary":394,"conditions":395,"keywords":4,"overallStatus":396,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":398,"startDateStruct":400,"completionDateStruct":402,"leadSponsor":404,"locationsCount":40},"100389018","phase-3-angiotensin-converting-enzyme-inhibitors-in-treatment-of-covid-19-100389018","NCT04345406","Angiotensin Converting Enzyme Inhibitors in Treatment of Covid 19","Randomized Trial of ACEIs in Treatment of COVID-19","Inclusion Criteria:\n\n* Patients infected with covid 19\n\nExclusion Criteria:\n\n* allergy or contraindications to the drug",{"count":392,"type":21},60,[352],"ACEIs as treatment for COVID19",[26],"NOT_YET_RECRUITING","2020-04-11",{"date":399,"type":32},"2020-04-14",{"date":401,"type":21},"2020-04-15",{"date":403,"type":21},"2029-12-01",{"name":363,"class":39}]